A
Avivit Cahn
Researcher at Hebrew University of Jerusalem
Publications - 106
Citations - 5248
Avivit Cahn is an academic researcher from Hebrew University of Jerusalem. The author has contributed to research in topics: Dapagliflozin & Type 2 diabetes. The author has an hindex of 25, co-authored 89 publications receiving 3651 citations. Previous affiliations of Avivit Cahn include Hadassah Medical Center.
Papers
More filters
Journal ArticleDOI
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker,Stephen D. Wiviott,Itamar Raz,KyungAh Im,Erica L. Goodrich,Marc P. Bonaca,Ofri Mosenzon,Eri Toda Kato,Avivit Cahn,Remo H.M. Furtado,Deepak L. Bhatt,Lawrence A. Leiter,Darren K. McGuire,John P.H. Wilding,Marc S. Sabatine +14 more
TL;DR: SGLT2i have moderate benefits on atherosclerotic major adverse cardiovascular events that seem confined to patients with established atheroscerotic cardiovascular disease, however, they have robust benefits on reducing hospitalisation for heart failure and progression of renal disease regardless of existing atherosclerosis or a history of heart failure.
Journal ArticleDOI
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Thomas A Zelniker,Stephen D. Wiviott,Itamar Raz,KyungAh Im,Erica L. Goodrich,Remo H.M. Furtado,Marc P. Bonaca,Ofri Mosenzon,Eri Toda Kato,Avivit Cahn,Deepak L. Bhatt,Lawrence A. Leiter,Darren K. McGuire,John P.H. Wilding,Marc S. Sabatine +14 more
TL;DR: GLP1-RA and SGLT2i reduce atherosclerotic MACE to a similar degree in patients with established atherosclerosis cardiovascular disease, whereas SGLG2i has a more marked effect on preventing hospitalization for heart failure and progression of kidney disease.
Journal ArticleDOI
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Ofri Mosenzon,Stephen D. Wiviott,Avivit Cahn,Aliza Rozenberg,Ilan Yanuv,Erica L. Goodrich,Sabina A. Murphy,Hiddo J.L. Heerspink,Thomas A Zelniker,Jamie P. Dwyer,Deepak L. Bhatt,Lawrence A. Leiter,Darren K. McGuire,John P.H. Wilding,Eri Toda Kato,Ingrid Gause-Nilsson,Martin Fredriksson,Peter A. Johansson,Anna Maria Langkilde,Marc S. Sabatine,Itamar Raz +20 more
TL;DR: Both the cardiorenal and renal-specific composite outcomes were improved with dapagliflozin versus placebo across various prespecified subgroups, including those defined by baseline eGFR.
Journal ArticleDOI
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Eri Toda Kato,Michael G. Silverman,Ofri Mosenzon,Thomas A Zelniker,Avivit Cahn,Remo H.M. Furtado,Julia F Kuder,Sabina A. Murphy,Deepak L. Bhatt,Lawrence A. Leiter,Darren K. McGuire,John P.H. Wilding,Marc P. Bonaca,Christian T. Ruff,Akshay S. Desai,Shinya Goto,Peter A. Johansson,Ingrid Gause-Nilsson,Per Johanson,Anna Maria Langkilde,Itamar Raz,Marc S. Sabatine,Stephen D. Wiviott +22 more
TL;DR: In the first sodium-glucose cotransporter 2 inhibitor cardiovascular outcome trial to evaluate patients with type 2 diabetes mellitus stratified by EF, it is found that dapagliflozin reduced HHF in patients with and without HFrEF and reduced cardiovascular death and all-cause mortality in Patients with HFr EF.
Journal ArticleDOI
Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial.
Ofri Mosenzon,Gil Leibowitz,Deepak L. Bhatt,Avivit Cahn,Boaz Hirshberg,Cheryl Wei,KyungAh Im,Aliza Rozenberg,Ilan Yanuv,Christina Stahre,Kausik K. Ray,Nayyar Iqbal,Eugene Braunwald,Benjamin M. Scirica,Itamar Raz +14 more
TL;DR: Treatment with saxagliptin improved ACR, even in the normoalbuminuric range, without affecting eGFR, and the beneficial effect of saxagLIptin on albuminuria could not be explained by its effect on glycemic control.